Posaconazole (Oral)

Medically reviewed by Drugs.com. Last updated on Apr 10, 2022.

Commonly used brand name(s)

In the U.S.

• Noxafil
• Noxafil PowderMix

Available Dosage Forms:

• Tablet, Delayed Release
• Suspension

Therapeutic Class: Antifungal

Chemical Class: Triazole

Uses for posaconazole

Posaconazole delayed-release tablets, oral suspension, and delayed-release oral suspension are used to prevent certain fungus (yeast) infections (eg, invasive Aspergillus or Candida infections) in patients who have a weakened immune system (eg, hematopoietic stem cell transplant or HSCT recipients, or patients with blood cancers).

Posaconazole delayed-release tablets is also used to treat invasive aspergillosis.

Posaconazole oral suspension is also used to treat a fungus infection of the mouth or throat called oral thrush (candidiasis). Posaconazole oral suspension may be used as an initial treatment or after treatment with other antifungal medicines (eg, itraconazole or fluconazole) have failed.

Posaconazole is available only with your doctor's prescription.

Before using posaconazole

In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For posaconazole, the following should be considered:

Allergies

Tell your doctor if you have ever had any unusual or allergic reaction to posaconazole or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.

Pediatric

Appropriate studies performed to date have not demonstrated pediatric-specific problems that would limit the usefulness of posaconazole delayed-release tablets, oral suspension, and delayed-release oral suspension in children 2 years of age and older to prevent fungus infections. However, safety and efficacy have not been established in children younger than 2 years of age. Use of delayed-release oral suspension in children weighing more than 40 kilograms (kg) is not recommended.

Appropriate studies performed to date have not demonstrated pediatric-specific problems that would limit the usefulness of posaconazole delayed-release tablets in children 13 years of age and older to treat invasive aspergillosis. Safety and efficacy have been established.

Appropriate studies performed to date have not demonstrated pediatric-specific problems that would limit the usefulness of posaconazole oral suspension in children 13 years of age and older to treat oral thrush (candidiasis). Safety and efficacy have been established.

Geriatric

Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of posaconazole in the elderly.

Breastfeeding

There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.

Interactions with medicines

Although certain medicines should not be used together at all, in other cases t...